Ibuprofen - Oxford Pharmascience

Drug Profile

Ibuprofen - Oxford Pharmascience

Alternative Names: Ibuprofen oral suspension - Oxford Pharmascience; Ibuprofen-layered double hydroxide; Ibuprofen-LDH; OXP 001; OXP 002; OXProfen; OXPzero™ Ibuprofen; Reduced gastric irriation ibuprofen; Taste-masked ibuprofen suspension

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford Pharmascience
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Musculoskeletal pain

Most Recent Events

  • 27 Sep 2017 Suspended - Phase-I for Musculoskeletal pain in United Kingdom, pending conclusion of a strategic review (PO)
  • 03 May 2017 Oxford Pharmascience completes a phase I pharmacokinetics trial of ibuprofen-LDH in Healthy volunteers in United Kingdom (PO) (NCT02974361)
  • 31 Mar 2017 Oxford Pharmascience receives feedback on IND from the US FDA for OXPzero™ Ibuprofen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top